Boron Neutron Capture Therapy (BNCT)
Boron Neutron Capture Therapy (BNCT) has entered a clinical renaissance in 2026, transitioning from research reactors to hospital-based accelerator systems for treating invasive, difficult-to-reach tumors.
The "Biological Scalpel": BNCT is a cell-selective radiotherapy. A boron-10 drug accumulates in cancer cells, which are then irradiated with low-energy neutrons. This triggers a localized nuclear fission that destroys the malignant cell from within while sparing healthy tissue only micrometers away.
Accelerator-Based Accessibility: The 2026 breakthrough is the deployment of Electrostatic Quadrupole (ESQ) accelerators. These compact units fit in oncology wings, removing the need for nuclear reactors and allowing clinicians to personalize neutron beams with real-time PET/MRI guidance.
Targeted Precision: New "second-generation" boron agents, such as boronated peptides, have achieved a tumor-to-healthy-tissue uptake ratio of 4:1, making BNCT a primary option for recurrent head-and-neck cancers and glioblastomas.